Ustekinumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 2 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Ustekinumab biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ustekinumab biosimilar is expected to reach an annual total of $812 mn by 2038 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ustekinumab biosimilar Overview
Ustekinumab biosimilar (CTP-43) is under development for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. It is formulated as a solution and administered through subcutaneous and intravenous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.
Celltrion is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has an operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea.
The company reported revenues of (Won) KRW1,911,601.3 million for the fiscal year ended December 2021 (FY2021), an increase of 3.4% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 38.3% in FY2020. In FY2021, the company recorded a net margin of 30.1%, compared to a net margin of 27.6% in FY2020. The company reported revenues of KRW645,637.4 million for the third quarter ended September 2022, a decrease of 42.7% over the previous quarter.
For a complete picture of Ustekinumab biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.